The Role of the Amylin Analogue Cagrilintide in Bone Metabolism

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-517883-49-00

Acronym

NN9388-8175

Enrollment

144

Registered

2025-03-21

Start date

2025-05-28

Completion date

Unknown

Last updated

2025-12-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

confirmation of postmenopausal status requires low levels of anti-Müllerian hormone (AMH) and inhibin B)., Female (aged between 50-70 years (both included)) with obesity (BMI ≥ 30.0 kg/m2) of post-menopausal state at screening (defined as minimum 12 months of amenorrhea and high levels of follicular stimulating hormone (FSH) ≥16 UI/L. In cases of uncertainty

Interventions

None listed

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Countries

Denmark

Outcome results